Dtsch Med Wochenschr 2010; 135(25/26): 1312-1314
DOI: 10.1055/s-0030-1255161
Klinischer Fortschritt | Commentary

© Georg Thieme Verlag KG Stuttgart · New York

Immunologie 2010

Immunology 2010G. M. N. Behrens1 , R. E. Schmidt1
  • 1Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover
Further Information

Publication History

Publication Date:
16 June 2010 (online)

Was ist neu?

  • Genetische Fiebersyndrome: Innovative Biologika zugelassen.

  • Primäre Immundefekte: Von der genetischen Assoziation zur Funktion des Immunsystems.

  • Stammzelltransplantation und Gentherapie bei Immundefekten: Fortschritte nach Rückschlägen.

  • Hereditäres Angioödem: Neue genetische Assoziationen, neue Medikamente.

Literatur

  • 1 Aiuti A, Cattaneo F, Galimberti S. et al . Gene therapy for immunodeficiency due to adenosine deaminase deficiency.  N Engl J Med. 2009;  360 447-458
  • 2 Boztug K, Appaswamy G, Ashikov A. et al . A syndrome with congenital neutropenia and mutations in G6PC3.  N Engl J Med. 2009;  360 32-43
  • 3 Craig T J, Levy R J, Wasserman R L. et al . Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.  J Allergy Clin Immunol. 2009;  124 801-808
  • 4 Duan Q L, Binkley K, Rouleau G A. Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema.  J Allergy Clin Immunol. 2009;  123 906-910
  • 5 Glocker E O, Hennigs A, Nabavi M. et al . A homozygous CARD9 mutation in a family with susceptibility to fungal infections.  N Engl J Med. 2009;  361 1727-1735
  • 6 Hentges F, Hilger C, Kohnen M, Gilson G. Angioedema and estrogen-dependent angioedema with activation of the contact system.  J Allergy Clin Immunol. 2009;  123 262-264
  • 7 Notarangelo L D, Fischer A. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies . Primary immunodeficiencies: 2009 update.  J Allergy Clin Immunol. 2009;  124 1161-1178
  • 8 Lachmann H J, Kone-Paut I, Kuemmerle-Deschner J B. et al . Use of canakinumab in the cryopyrin-associated periodic syndrome.  N Engl J Med. 2009;  360 2416-2425
  • 9 Neven B, Leroy S, Decaluwe H. et al . Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency.  Blood. 2009;  113 4114-4124
  • 10 Routes J M, Grossman W J, Verbsky J. et al . Statewide newborn screening for severe T-cell lymphopenia.  JAMA. 2009;  302 2465-2470
  • 11 Stein S, Ott M G, Schultze-Strasser S. et al . Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.  Nat Med. 2010;  16 198-204
  • 12 Straathof K C, Rao K, Eyrich M. et al . Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.  Lancet. 2009;  374 912-920
  • 13 US Food and Drug Administration .FDA labelling information – Kalbitor (ecallantide). FDA website [online]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125277lbl.pdf
  • 14 Warnatz K, Salzer U, Rizzi M. et al . B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans.  Proc Natl Acad Sci U S A. 2009;  106 13945-13950

Prof. Dr. med. Georg Behrens

Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Phone: 0511/532-5713

Fax: 0511/532-5324

Email: Behrens.georg@mh-hannover.de

    >